Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
Diabetes ; 69(4): 724-735, 2020 04.
Artículo en Inglés | MEDLINE | ID: mdl-32029482

RESUMEN

Diabetic retinopathy (DR) is a widespread vision-threatening disease, and neuroretinal abnormality should be considered as an important problem. Brain-derived neurotrophic factor (BDNF) has recently been considered as a possible treatment to prevent DR-induced neuroretinal damage, but how BDNF is upregulated in DR remains unclear. We found an increase in hydrogen peroxide (H2O2) in the vitreous of patients with DR. We confirmed that human retinal endothelial cells secreted H2O2 by high glucose, and H2O2 reduced cell viability of MIO-M1, Müller glia cell line, PC12D, and the neuronal cell line and lowered BDNF expression in MIO-M1, whereas BDNF administration recovered PC12D cell viability. Streptozocin-induced diabetic rats showed reduced BDNF, which is mainly expressed in the Müller glia cell. Oral intake of eicosapentaenoic acid ethyl ester (EPA-E) ameliorated BDNF reduction and oscillatory potentials (OPs) in electroretinography (ERG) in DR. Mass spectrometry revealed an increase in several EPA metabolites in the eyes of EPA-E-fed rats. In particular, an EPA metabolite, 18-hydroxyeicosapentaenoic acid (18-HEPE), induced BDNF upregulation in Müller glia cells and recovery of OPs in ERG. Our results indicated diabetes-induced oxidative stress attenuates neuroretinal function, but oral EPA-E intake prevents retinal neurodegeneration via BDNF in Müller glia cells by increasing 18-HEPE in the early stages of DR.


Asunto(s)
Factor Neurotrófico Derivado del Encéfalo/farmacología , Retinopatía Diabética/metabolismo , Ácido Eicosapentaenoico/farmacología , Células Endoteliales/metabolismo , Células Ependimogliales/metabolismo , Estrés Oxidativo/efectos de los fármacos , Neuronas Retinianas/metabolismo , Animales , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Diabetes Mellitus Experimental/metabolismo , Electrorretinografía , Células Endoteliales/efectos de los fármacos , Células Ependimogliales/efectos de los fármacos , Ácidos Grasos Omega-3/farmacología , Femenino , Humanos , Peróxido de Hidrógeno/metabolismo , Masculino , Estrés Oxidativo/fisiología , Ratas , Ratas Sprague-Dawley , Neuronas Retinianas/efectos de los fármacos
2.
Sci Rep ; 7(1): 2640, 2017 05 25.
Artículo en Inglés | MEDLINE | ID: mdl-28572674

RESUMEN

Silicone oil (SO) is an intraocular surgical adjuvant that reduces the surgical complications in refractory retinal diseases, although membrane and cellular proliferation is often seen even in SO-filled eyes. We hypothesised that the fluid in the space between the SO and the retina, named the "sub-silicone oil fluid (SOF)", enhances these biological responses. We proposed a safe method for SOF extraction. We also analysed inflammatory cytokine expressions and SOF osmotic pressures from eyes with rhegmatogenous retinal detachment (RRD), proliferative diabetic retinopathy (PDR), proliferative vitreoretinopathy (PVR) and macular hole-associated retinal detachment (MHRD). Interleukin (IL)-10, IL-12p40, IL-6, monocyte chemotactic protein-1, and vascular endothelial growth factor (VEGF) in the SOF with PVR were significantly higher than in those with RRD or MHRD. Fibroblast growth factor-2, IL-10, IL-12p40, IL-8, VEGF, and transforming growth factor beta 1 levels in eyes with exacerbated PDR indicated a significantly higher expression than those with simple PDR. IL-6 and tumour necrosis factor alpha in eyes with exacerbated PVR demonstrated a significantly higher expression than in those with simple PVR. However, there was no difference in SOF osmotic pressure between group of each disease. These studies indicate that disease-specific SOF is a significant reflection of disease status.


Asunto(s)
Citocinas/genética , Enfermedades de la Retina/genética , Aceites de Silicona/administración & dosificación , Vitreorretinopatía Proliferativa/genética , Adulto , Anciano , Proliferación Celular/efectos de los fármacos , Retinopatía Diabética/tratamiento farmacológico , Retinopatía Diabética/genética , Retinopatía Diabética/patología , Retinopatía Diabética/cirugía , Femenino , Regulación de la Expresión Génica/genética , Humanos , Masculino , Persona de Mediana Edad , Presión Osmótica , Retina/efectos de los fármacos , Retina/metabolismo , Retina/patología , Retina/cirugía , Desprendimiento de Retina/genética , Desprendimiento de Retina/patología , Desprendimiento de Retina/cirugía , Enfermedades de la Retina/tratamiento farmacológico , Enfermedades de la Retina/patología , Enfermedades de la Retina/cirugía , Aceites de Silicona/efectos adversos , Vitrectomía/efectos adversos , Vitreorretinopatía Proliferativa/tratamiento farmacológico , Vitreorretinopatía Proliferativa/patología , Vitreorretinopatía Proliferativa/cirugía
3.
Oxid Med Cell Longev ; 2017: 9548767, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28243361

RESUMEN

Purpose. To compare serum levels of malondialdehyde (MDA) in patients with wet age-related macular degeneration (wAMD), patients with dry AMD (dAMD), and patients without AMD and to evaluate the efficacy of nutritional supplementation for treating elevated serum MDA in patients with wAMD. Methods. MDA levels were measured in sera from 20 patients with wAMD, 20 with dAMD, and 24 without AMD. Patients with wAMD were randomized to receive or not receive nutritional supplementation (10 patients in each group), and MDA levels were measured after 3 months of treatment. Results. MDA levels in patients with wAMD were significantly greater compared with patients without AMD. In eyes with wAMD, there was a significant correlation between MDA levels and choroidal neovascularization lesion area. Serum MDA levels decreased in most patients that received supplementation and significantly increased in those who did not. Conclusion. Baseline serum MDA levels were elevated in patients with wAMD, and MDA levels were directly correlated with choroidal neovascularization lesion area. In addition, nutritional supplementation appeared to exert a protective effect against oxidative stress in patients with wAMD.


Asunto(s)
Neovascularización Coroidal/dietoterapia , Suplementos Dietéticos , Degeneración Macular/dietoterapia , Malondialdehído/sangre , Degeneración Macular Húmeda/dietoterapia , Anciano , Neovascularización Coroidal/sangre , Neovascularización Coroidal/patología , Femenino , Humanos , Degeneración Macular/sangre , Degeneración Macular/patología , Masculino , Degeneración Macular Húmeda/sangre , Degeneración Macular Húmeda/patología
4.
Acta Ophthalmol ; 90(5): e344-8, 2012 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-22676067

RESUMEN

PURPOSE: To evaluate the safety profile of a brimonidine extended release intravitreal implant, in normotensive rabbit eyes. METHODS: Devices were made from hollow poly-l-lactic acid (PLA) tubes and contained hundred micrograms of brimonidine pamoate. Device was injected intravitreally in one eye of 12 New Zealand pigmented rabbits, whereas other eye was injected with a sham implant in masked fashion. Ocular examination was conducted at baseline and months 1, 3 and 6 including dilated fundus examination and electro-retinogram (ERG). Four rabbits were sacrificed at each time-point for retinal histology. ERG data were compared between groups and time-points using anova. RESULTS: No complications were reported from either eye of any rabbits over a 6-month period. Photopic A wave was reduced in the control eye at 1 month compared with baseline (p < 0.01). There was no significant difference in other ERG parameters between the groups at different time-points. Gross retinal histology was normal at all time-points. CONCLUSION: Extended release intravitreal brimonidine device was found to be safe and in normotensive rabbit eyes.


Asunto(s)
Antihipertensivos/toxicidad , Portadores de Fármacos , Quinoxalinas/toxicidad , Cuerpo Vítreo/efectos de los fármacos , Animales , Antihipertensivos/administración & dosificación , Tartrato de Brimonidina , Adaptación a la Oscuridad/fisiología , Evaluación Preclínica de Medicamentos , Implantes de Medicamentos , Electrorretinografía , Masculino , Poliésteres , Quinoxalinas/administración & dosificación , Conejos , Retina/efectos de los fármacos , Retina/fisiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA